Skip to main content
RYTM
NASDAQ Life Sciences

Rhythm Tops Q3 Revenue Estimates, Lands $750M Term Loan, and Maps Bivamelagon Phase 3

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$89.5
Mkt Cap
$6.434B
52W Low
$74.5
52W High
$122.2
52W Position info
20% above low
Off High info
27% below high
Rel. Volume info
3.0× avg
Market data snapshot near publication time

RYTM sits 20% above its 52-week low of $74.5 on elevated volume (3.0× avg).

Summary

Rhythm posted Q3 revenue of $92.1 million, up 29% sequentially, and disclosed a new $750 million five-year term loan alongside a restructured LG Chem royalty deal as bivamelagon advances into Phase 3.


Key Events · Earnings and Guidance · RYTM

  • Q3 Revenue Jumps 29% Sequentially

    Net product revenue from IMCIVREE reached $92.1 million, up from $71.3 million in Q2 2026. U.S. revenue accounted for $67.5 million, or 73% of the total, with ex-U.S. revenue at $24.7 million.

  • $750M Term Loan Secured

    The five-year facility, led by KKR's HealthCare Royalty with Blackstone Life Sciences, carries SOFR+4.60% (1.00% floor), 1.0% OID and no amortization. Its $250 million initial draw lifts pro-forma cash to about $570.9 million ($320.9M + $250M).

  • LG Chem Royalty Restructured

    To cut the MC4R portfolio royalty to 1%, Rhythm will pay $350 million over four years: $70 million within 15 business days, then $100 million in September 2027, $100 million in September 2028 and $80 million in September 2029.

  • Bivamelagon Heads to Phase 3

    Pivotal trials are planned in acquired hypothalamic obesity (52 weeks, BMI reduction endpoint) and Prader-Willi syndrome (26 weeks, hyperphagia endpoint), with the acquired-HO trial starting by year-end 2026.


Analysis · RYTM · Life Sciences

The quarter's $92.1 million in revenue beat the prior quarter by 29%, as the U.S. acquired-HO launch scaled past 700 start forms. More important for the balance sheet, a new $750 million five-year term loan led by KKR's HealthCare Royalty with Blackstone provides a $250 million initial draw that lifts pro-forma cash to roughly $570.9 million ($320.9M + $250M), removing near-term financing risk. Cost is the trade-off: the LG Chem amendment swaps a low-to-mid-single-digit royalty for a 1% royalty by paying $350 million over four years, including $70 million within 15 business days, while the loan carries SOFR+4.60% with a 1.00% floor. Next value driver is bivamelagon's move into Phase 3 in both acquired HO and Prader-Willi syndrome, with the acquired-HO trial starting by year-end 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RYTM was trading at $89.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $74.50 to $122.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 16, 2026, 4:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $107.31
Real-time Price: $117.01 info
Change: +$9.70 (+9%) info
Market Cap: $8.085B info
RYTM
Nov 06, 2026, 11:06 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $109.39
Real-time Price: $117.01 info
Change: +$7.62 (+7%) info
Market Cap: $8.085B info
RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $117.01 info
Change: +$7.26 (+7%) info
Market Cap: $8.085B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $117.01 info
Change: +$21.80 (+23%) info
Market Cap: $8.085B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $117.01 info
Change: +$31.31 (+37%) info
Market Cap: $8.085B info